Re-evaluating the placebo response in recent canine dietary epilepsy trials

Area of Science:

• Veterinary Neurology
• Clinical Pharmacology
• Animal Health Research

Background:

• The placebo response is a significant factor in clinical trials, yet its magnitude in canine epilepsy is poorly understood.
• Accurate assessment of new antiepileptic drugs relies on understanding and accounting for placebo effects in trial design.

Purpose of the Study:

• To investigate the placebo response magnitude in canine epilepsy trials.
• To test the hypothesis that prospective crossover designs reduce placebo effects.
• To analyze seizure frequency changes during placebo treatment in different trial phases.

Main Methods:

• Analysis of six-month seizure data from 60 dogs with idiopathic epilepsy across three multicenter studies.
• Comparison of monthly seizure frequency during placebo treatment versus baseline.
• Differentiated analysis based on early (Phase 1) versus late (Phase 2) placebo administration.

Main Results:

• No placebo response was detected; instead, monthly seizure frequency increased during placebo treatment (2.95 vs. 2.30 seizures/month).
• Dogs receiving placebo in Phase 2 showed a significant seizure frequency increase compared to baseline (p=0.0036).
• No significant difference from baseline was observed for dogs receiving placebo in Phase 1.

Conclusions:

• Canine epilepsy trials exhibit considerable placebo response variability, contrary to limited prior data.
• A significant phase effect exists, with later placebo exposure increasing seizure frequency.
• Trial designs must consider this phase effect for accurate antiepileptic drug efficacy assessment.